Cargando…

Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis

The Chinese community-acquired pneumonia (CAP) Diagnosis and Treatment Guideline 2020 recommends quinolone antibiotics as the initial empirical treatment options for CAP. However, patients with pulmonary tuberculosis (PTB) are often misdiagnosed with CAP because of the similarity of symptoms. Moxifl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Mingye, Chi, Zhuoyuan, Pan, Xingming, Yin, Yue, Tang, Wenxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028707/ https://www.ncbi.nlm.nih.gov/pubmed/35457683 http://dx.doi.org/10.3390/ijerph19084816

Ejemplares similares

Efficacy and Safety of Nemonoxacin in Outpatients with Community-Acquired Pneumonia
por: Zhao, Bo, et al.
Publicado: (2020)

The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials
por: Chang, Shen-Peng, et al.
Publicado: (2019)

Safety and Efficacy of Nemonoxacin vs Levofloxacin in Patients With Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Control Trials
por: Khan, Alina S, et al.
Publicado: (2023)

Retrospective Comparison of Levofloxacin and Moxifloxacin on Multidrug-Resistant Tuberculosis Treatment Outcomes
por: Lee, Jinwoo, et al.
Publicado: (2011)

Integrative population pharmacokinetic/pharmacodynamic analysis of nemonoxacin capsule in Chinese patients with community-acquired pneumonia
por: Chen, Yuancheng, et al.
Publicado: (2023)

Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease
por: Meng, Weiwei, et al.
Publicado: (2023)

Population Pharmacokinetics of Levofloxacin and Moxifloxacin, and the Probability of Target Attainment in Ethiopian Patients with Multidrug-Resistant Tuberculosis
por: Sidamo, Temesgen, et al.
Publicado: (2022)

Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin
por: Sugioka, Koji, et al.
Publicado: (2009)

The treatment effect of Levofloxacin, Moxifloxacin, and Gatifloxacin contained in the conventional therapy regimen for pulmonary tuberculosis: Systematic review and network meta-analysis
por: He, Yiyue, et al.
Publicado: (2022)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model
por: Zhao, Mingye, et al.
Publicado: (2023)

Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach
por: Pienaar, Elsje, et al.
Publicado: (2017)

Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China
por: Zheng, Huiwen, et al.
Publicado: (2021)

Review of nemonoxacin with special focus on clinical development
por: Qin, Xiaohua, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis
por: Zhao, Mingye, et al.
Publicado: (2022)

Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia
por: Endimiani, Andrea, et al.
Publicado: (2005)

Effects of the Fluoroquinolones Moxifloxacin and Levofloxacin on the QT Subintervals: Sex Differences in Ventricular Repolarization
por: Täubel, Jӧrg, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against Streptococcus Pneumoniae
por: Li, Xin, et al.
Publicado: (2021)

Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19?
por: Karampela, Irene, et al.
Publicado: (2020)

Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia
por: Tanaseanu, Cristina, et al.
Publicado: (2009)

Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China
por: Kong, Yaoyao, et al.
Publicado: (2023)

In Vitro Resistance Development to Nemonoxacin in Streptococcus pneumoniae: A Unique Profile for a Novel Nonfluorinated Quinolone
por: Roychoudhury, Siddhartha, et al.
Publicado: (2016)

Prescription of Levofloxacin and Moxifloxacin in Select Hospitals in Uganda: A Pilot Study to Assess Guideline Concordance
por: Nambasa, Victoria, et al.
Publicado: (2020)

Effects of probenecid and cimetidine on the pharmacokinetics of nemonoxacin in healthy Chinese volunteers
por: Zhang, Yi-fan, et al.
Publicado: (2016)

Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin
por: Yu, Xia, et al.
Publicado: (2016)

Pulmonary Targeting of Inhalable Moxifloxacin Microspheres for Effective Management of Tuberculosis
por: Vishwa, Bhavya, et al.
Publicado: (2021)

A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Ferrara, Anna M
Publicado: (2007)

Efficacy and safety of sequential IV/PO moxifloxacin for the treatment of severe community-acquired pneumonia
por: Lode, H, et al.
Publicado: (2002)

The role of moxifloxacin in tuberculosis therapy
por: Gillespie, Stephen H.
Publicado: (2016)

Switch therapy in hospitalized patients with community-acquired pneumonia: Tigecycline vs. Levofloxacin
por: Ramirez, Julio A, et al.
Publicado: (2012)

Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies
por: Grillon, Antoine, et al.
Publicado: (2016)

Pharmacokinetics and aqueous humor penetration of levofloxacin 1.5% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2016)

Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI)
por: Kuzman, Ilija, et al.
Publicado: (2014)

Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS
por: Rahmel, Tim, et al.
Publicado: (2017)

Safety of oral nemonoxacin: A systematic review of clinical trials and postmarketing surveillance
por: Yuan, Jinyi, et al.
Publicado: (2022)

Tigecycline Versus Levofloxacin in Hospitalized Patients With Community-Acquired Pneumonia: An Analysis of Risk Factors
por: Dartois, Nathalie, et al.
Publicado: (2013)

Lithium Intoxication: A Possible Interaction with Moxifloxacin
por: Kayipmaz, Selvi, et al.
Publicado: (2017)

Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea
por: Cho, Yongil, et al.
Publicado: (2018)

Moxifloxacin modulates inflammation during murine pneumonia
por: Beisswenger, Christoph, et al.
Publicado: (2014)

Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy
por: Zhou, Bo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0krmd70tfumttfrpp1eq46dovh